文献速递治疗药物监测与药物基因组学肝肾功能剂量调整

依库珠单抗减量应考量其药代动力学的非线性特征

Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.
PubMed 文献 · Br J Clin Pharmacol · 2024-02-19

该研究基于44例非典型溶血性尿毒症综合征和C3肾小球病患者共377个依库珠单抗血清浓度,采用群体药代动力学方法分析其靶点介导消除,并模拟给药方案预测目标 attainment 概率(谷浓度>100 mg/L)。结果显示依库珠单抗药代动力学呈非线性,含一级消除(CL=1.318 mL/day/kg)和米氏消除(Vmax=26.07 mg/day,Km=24.06 mg/L),分布容积(72.39 mL/kg)和清除率与体重相关。模拟预测每21天1200 mg可使50 kg和90 kg体重患者分别有85%和76%维持治疗暴露。

要点

  • 依库珠单抗消除呈非线性,治疗浓度下靶点介导消除明显。
  • 每21天1200 mg模拟:50 kg患者85%、90 kg患者76%维持谷浓度>100 mg/L。

核心结论

  • 依库珠单抗药代动力学呈非线性,减量给药需考虑靶点介导消除。
  • 非线性模型较线性模型能更好预测依库珠单抗浓度。

研究设计与样本

  • 基于44例患者377个依库珠单抗血清浓度的群体药代动力学分析。
  • 患者接受依库珠单抗治疗非典型溶血性尿毒症综合征或C3肾小球病。
  • 计算临界浓度并模拟给药方案预测目标 attainment 概率。

主要发现

  • 药代动力学为一级消除(CL=1.318 mL/day/kg)和米氏消除(Vmax=26.07 mg/day,Km=24.06 mg/L)的混合。
  • 分布容积(72.39 mL/kg)和清除率与体重相关。

关键数值与推荐

  • 目标谷浓度>100 mg/L。
  • 模拟每21天1200 mg依库珠单抗:50 kg体重患者85%达标,90 kg体重患者76%达标。

临床怎么用

  • 临床减量依库珠单抗时应考虑非线性药代动力学,避免浓度不足。
  • 治疗药物监测可结合非线性模型优化个体化给药。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Eculizumab is a monoclonal antibody targeting complement protein C5 used in renal diseases. As recommended dosing regimen leads to unnecessarily high concentrations in some patients, tailored dosing therapeutic drug monitoring was proposed to reduce treatment cost. The objectives of the present work were (i) to investigate the target-mediated elimination of eculizumab and (ii) whether a pharmacokinetic model integrating a nonlinear elimination allows a better prediction of eculizumab concentrations than a linear model. METHODS: We analysed 377 eculizumab serum concentrations from 44 patients treated for atypical haemolytic uraemic syndrome and C3 glomerulopathy with a population pharmacokinetic approach. Critical concentrations (below which a non-log-linear decline of concentration over time is evidenced) were computed to estimate the relevance of the target-mediated elimination. Simulations of dosing regimens were then performed to predict probabilities of target attainment (i.e. trough >100 mg/L). RESULTS: Pharmacokinetics of eculizumab was nonlinear and followed a mixture of first-order (CL = 1.318 mL/day/kg) and Michaelis-Menten elimination (Vmax = 26.07 mg/day, Km = 24.06 mg/L). Volume of distribution (72.39 mL/kg) and clearance were weight-dependent. Critical concentrations (Vmax/CL) ranged from 144.7 to 759.7 mg/L and were inversely related to body weight (P = .013). Nonlinearity was thus noticeable at therapeutic concentrations. Simulations predicted that 1200 mg of eculizumab every 21 days would allow 85% and 76% of patients to maintain a therapeutic exposure, for 50 or 90 kg body weight, respectively. CONCLUSIONS: Our study investigates the nonlinear elimination of eculizumab and discusses the importance of accounting for eculizumab target-mediated elimination in therapeutic drug monitoring.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Le Tilly O, Gatault P, Semlali S, et al. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics. Br J Clin Pharmacol. 2024. PMID: 38373846. doi:10.1111/bcp.16019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。